Clinical Trial Update: Efficacy and Safety of Navarixin (SCH 527123) in Participants With Allergen-Induced Asthma (P05363) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing efficacy and safety of Navarixin (SCH 527123) in participants with allergen-inducing asthma has completed with results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Navarixin (navarixin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2014-10-06